Vendors

Vendor FAQ

• What did Omnicare announce?

  • Omnicare initiated a voluntary court-supervised Chapter 11 process to resolve issues related to the recent litigation in the U.S. District Court for the Southern District of New York.
  • The Company also intends to use this process to address other financial challenges facing the broader long-term care pharmacy industry.
  • On May 13, 2026, Omnicare received Court approval to proceed with a sale of the Company’s business to GenieRx.
  • This approval marks an important step forward in our court-supervised sale process and provides a clear path to close the transaction later this year, subject to regulatory approval and customary closing conditions.
  • As we move through the court-supervised process, we remain fully committed to delivering safe and reliable pharmacy and clinical services to our customers and residents.

• Who will be the new owner of Omnicare?

  • The Court approved GenieRx as the buyer for Omnicare’s business in full.
  • GenieRx is a joint partnership between private investment firm Milrose Capital LLC and health-care investment and management firm Integro Asset Management LLC, which does business as Integro Healthcare Services.
  • With GenieRx we will have the opportunity to strengthen how we serve, by staying disciplined in our operations, aligning closely with best practices and working in partnership with providers and communities that count on us.

• Why did Omnicare file for Chapter 11?

  • We were engaged in a civil lawsuit in the U.S. District Court for the Southern District of New York.
  • To resolve issues related to the litigation and address other financial challenges facing the broader long-term care pharmacy industry, Omnicare initiated a voluntary court-supervised Chapter 11 process.
  • This is a proactive step that enables us to move forward and help ensure the continued delivery of safe and reliable pharmacy and clinical services to our customers and residents.

• Does this mean Omnicare’s Chapter 11 process is over? When do you expect to close the sale?

  • This approval marks an important step forward and provides a clear path through this process to complete the transaction later this year, subject to regulatory approval and customary closing conditions.
  • Omnicare is continuing to operate as normal.
  • We remain focused on working closely with our customers and delivering safe, reliable pharmacy services.

• Does Omnicare have sufficient liquidity to continue operating?

  • Yes. We have access to sufficient cash to conduct normal operations during this process.
  • In connection with this process, we have received a commitment for new financing.
  • On September 24, 2025, the Court granted Omnicare interim approval to access a portion of these funds.
  • Along with cash generated from operations, this financing will provide sufficient liquidity for Omnicare to conduct normal operations during the court-supervised process.

• What does this mean for vendors and suppliers that support Omnicare?

  • As part of federal law under the U.S. Bankruptcy Code, we have to pay vendors and suppliers in full under normal terms for goods and services provided after the filing date.
  • We have access to sufficient cash to conduct normal operations during this process, including paying our vendors.
  • We rely on your cooperation – and the cooperation of all of our vendors – as you play a critical role in enabling us to provide safe and reliable pharmacy and clinical services for our customers and residents as we move through this process.

• Where can I find more information?

  • Additional stakeholder resources and information regarding the court-supervised process is available at www.OmnicareRestructuring.com.
  • Court filings and other information related to the proceedings, including instructions on how to file a proof of claim, are available on a separate website administered by the Company’s claims agent, Stretto, at https://cases.stretto.com/Omnicare, by calling Stretto representatives toll-free at (833) 570-5323 or (949) 276-9547 for calls originating outside of the U.S. or Canada, or by sending an email to TeamOmnicare@stretto.com.